Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Platinum-Resistant Ovarian Cancer

Key Inclusion Criteria:

1. Patients with histologically or cytologically confirmed diagnosis of advanced,
epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian
tube cancer who have all of the following:

1. serum CA-125 level ≥2x upper limit of normal (ULN) (in screening)

2. progression or relapse during or within 6 months of the most recent treatment
with a platinum-containing chemotherapy regimen

3. documented progression on the most recent line of therapy

4. no standard therapy options

2. Adequate organ and bone marrow function

3. Adequately controlled blood pressure

4. Life expectancy of at least 3 months

Key Exclusion Criteria:

1. Recent treatment with anti-Programmed Cell Death (PD-1)/PD-L1 therapy

2. No more than 3 prior lines of cytotoxic chemotherapy for platinum-resistant disease

3. Prior treatment with idelalisib (excluded from cemiplimab combination cohorts only)

4. Prior treatment with a Mucin 16 (MUC16)-targeted therapy (excluded from expansion
cohorts only)

5. Untreated or active primary brain tumor, central nervous system (CNS) metastases, or
spinal cord compression

6. History of clinically significant cardiac disease

Note: Other protocol Inclusion/Exclusion Criteria apply